Affordable Access

Multicenter trial of naloxone in Alzheimer's disease.

Authors
  • Henderson, V W
  • Roberts, E
  • Wimer, C
  • Bardolph, E L
  • Chui, H C
  • Damasio, A R
  • Eslinger, P J
  • Folstein, M F
  • Schneider, L S
  • Teng, E L
Type
Published Article
Journal
Annals of neurology
Publication Date
Apr 01, 1989
Volume
25
Issue
4
Pages
404–406
Identifiers
PMID: 2653175
Source
Medline
License
Unknown

Abstract

In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

Report this publication

Statistics

Seen <100 times